miRNA 시퀀스 및 어세이 시장 : 제품·서비스, 기술, 워크플로우, 최종사용자, 용도별 - 세계 예측(2025-2030년)

The miRNA Sequencing & Assay Market was valued at USD 333.35 million in 2023, expected to reach USD 380.21 million in 2024, and is projected to grow at a CAGR of 14.15%, to USD 841.92 million by 2030.

The miRNA Sequencing & Assay market embodies the expansive scope of technologies and methodologies designed to analyze microRNAs, critical regulators of gene expression. The necessity of miRNA sequencing arises from its potential applications in understanding diseases, including cancer, cardiovascular, and neurodegenerative disorders, offering significant prospects for biomarker discovery and personalized medicine. Its end-use scope spans academic research institutions, pharmaceutical and biotechnological companies, and clinical laboratories engaged in cutting-edge research. Influencing growth factors include advancements in sequencing technologies that enhance accuracy and cost-effectiveness, a rising focus on genomics in precision medicine, and expanded research funding. Latest potential opportunities lie in the increasing demand for non-invasive diagnostic tools, enabling early disease detection through liquid biopsies. Companies should exploit partnerships with research institutes to fast-track innovation and capitalize on the rising interest in RNA therapeutics. However, the market faces limitations from the high cost of sequencers and assays, the complexity of data interpretation, and regulatory challenges. Additionally, variability in data analysis and a lack of standardized protocols present challenges that require resolution for more widespread adoption. The best areas for innovation include developing affordable and user-friendly sequencing platforms, improving data analytics tools with AI integration for better interpretation, and expanding comprehensive databases for miRNA function. Collaborations with regulatory agencies could aid in establishing standards and addressing compliance concerns. The nature of the miRNA Sequencing & Assay market is dynamic, driven by technological advancement and the escalating demand for precision healthcare solutions. Companies that can navigate regulatory landscapes, invest in R&D to reduce costs, and broaden the understanding of miRNA's role in various conditions are well-positioned to sustain long-term growth and impact. Enhanced focus on training programs to skill scientists in miRNA technologies and data analysis can further catalyze market expansion and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving miRNA Sequencing & Assay Market

The miRNA Sequencing & Assay Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Introduction of various techniques to assess the miRNA sequence
  • Increased prevalence of infectious diseases
  • Surge in the number of cancer incidences
• Market Restraints
  • Lack of skilled professionals
• Market Opportunities
  • Growing popularity for cost effective sequencing techniques
  • Increase in the number of research in genetic segment
• Market Challenges
  • High initial investment on infrastructure

Porter's Five Forces: A Strategic Tool for Navigating the miRNA Sequencing & Assay Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the miRNA Sequencing & Assay Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the miRNA Sequencing & Assay Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the miRNA Sequencing & Assay Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the miRNA Sequencing & Assay Market

A detailed market share analysis in the miRNA Sequencing & Assay Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the miRNA Sequencing & Assay Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the miRNA Sequencing & Assay Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the miRNA Sequencing & Assay Market

A strategic analysis of the miRNA Sequencing & Assay Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the miRNA Sequencing & Assay Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Bio-Rad Laboratories, Inc., Global Life Sciences Solutions USA LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Integrated DNA Technologies, Inc, Lexogen GmbH, Meridian Bioscience Inc, New England Biolabs (UK) Ltd., Norgen Biotek Corp., Oxford Nanopore Technologies Limited, Rosetta Genomics Ltd., Sigma Aldrich Corp., System Biosciences, LLC, Thermo Fisher Scientific Inc., and TriLink BioTechnologies, Inc..

Market Segmentation & Coverage

This research report categorizes the miRNA Sequencing & Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Products and Services. The Products is further studied across Instruments, Library Preparation Kits, and Sequencing Consumables.
• Based on Technology, market is studied across Nanopore Sequencing, Sanger Sequencing, Sequencing By Oligonucleotide Ligation & Detection, and Single Molecule Real-Time (SMRT) Sequencing.
• Based on Workflow, market is studied across Data Analysis & Storage, Library Preparation, and Sequencing.
• Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Industry, and Research & Academic Institutes.
• Based on Application, market is studied across Autoimmune Disease, Cancer, Polyglutamine Diseases, and Schizophrenia.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Introduction of various techniques to assess the miRNA sequence
    • 5.1.1.2. Increased prevalence of infectious diseases
    • 5.1.1.3. Surge in the number of cancer incidences
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of skilled professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing popularity for cost effective sequencing techniques
    • 5.1.3.2. Increase in the number of research in genetic segment
  • 5.1.4. Challenges
    • 5.1.4.1. High initial investment on infrastructure
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. miRNA Sequencing & Assay Market, by Product & Service

• 6.1. Introduction
• 6.2. Products
  • 6.2.1. Instruments
  • 6.2.2. Library Preparation Kits
  • 6.2.3. Sequencing Consumables
• 6.3. Services

7. miRNA Sequencing & Assay Market, by Technology

• 7.1. Introduction
• 7.2. Nanopore Sequencing
• 7.3. Sanger Sequencing
• 7.4. Sequencing By Oligonucleotide Ligation & Detection
• 7.5. Single Molecule Real-Time (SMRT) Sequencing

8. miRNA Sequencing & Assay Market, by Workflow

• 8.1. Introduction
• 8.2. Data Analysis & Storage
• 8.3. Library Preparation
• 8.4. Sequencing

9. miRNA Sequencing & Assay Market, by End-User

• 9.1. Introduction
• 9.2. Contract Research Organizations
• 9.3. Pharmaceutical & Biotechnology Industry
• 9.4. Research & Academic Institutes

10. miRNA Sequencing & Assay Market, by Application

• 10.1. Introduction
• 10.2. Autoimmune Disease
• 10.3. Cancer
• 10.4. Polyglutamine Diseases
• 10.5. Schizophrenia

11. Americas miRNA Sequencing & Assay Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific miRNA Sequencing & Assay Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa miRNA Sequencing & Assay Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abcam PLC
• 2. Bio-Rad Laboratories, Inc.
• 3. Global Life Sciences Solutions USA LLC
• 4. HTG Molecular Diagnostics, Inc.
• 5. Illumina, Inc.
• 6. Integrated DNA Technologies, Inc
• 7. Lexogen GmbH
• 8. Meridian Bioscience Inc
• 9. New England Biolabs (UK) Ltd.
• 10. Norgen Biotek Corp.
• 11. Oxford Nanopore Technologies Limited
• 12. Rosetta Genomics Ltd.
• 13. Sigma Aldrich Corp.
• 14. System Biosciences, LLC
• 15. Thermo Fisher Scientific Inc.
• 16. TriLink BioTechnologies, Inc.